Abstract
Procurement and processing of human plasma for fractionation of therapeutic proteins or biological medicines used in clinical practice is a multi-billion dollar international trade. Together the private sector and public sector (non-profit) provide large amounts of safe and effective therapeutic plasma proteins needed worldwide. The principal therapeutic proteins produced by the dichotomous industry include gamma globulins or immunoglobulins (including pathogen-specific hyperimmune globulins, such as hepatitis B immune globulins) albumin, factor VIII and Factor IX concentrates. Viral inactivation, principally by solvent detergent and other processes, has proven highly effective in preventing transmission of enveloped viruses, viz. HBV, HIV, and HCV.
| Original language | English |
|---|---|
| Pages (from-to) | 88-93 |
| Number of pages | 6 |
| Journal | Biologicals |
| Volume | 37 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 2009 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being -
SDG 5 Gender Equality
Keywords
- Factor VIII
- IVIG
- Procurement of plasma
- Protein fractionation
- Viral inactivation
ASJC Scopus subject areas
- Biotechnology
- Bioengineering
- Applied Microbiology and Biotechnology
- General Immunology and Microbiology
- Pharmacology
Fingerprint
Dive into the research topics of 'Plasma fractionation issues'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS